November 10, 2022
Inequities and SDOH
  • A new analysis published in JAMA Psychiatry found that racial and ethnic disparities in buprenorphine treatment duration increased between 2006 and 2020, particularly during more recent years. The data revealed that the typical duration of treatment for Black and Hispanic patients was shorter compared to white patients. Furthermore, the percentage of minority patients who remained on buprenorphine for more than 180 days — the minimum recommended duration — was significantly below that of white patients. (Analysis here; Article here)